



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_479_25

You asked:

I would like to raise an FOI request, which I hope you will be able to help me with.

How many new patients were treated for Psoriasis by the Trust's Dermatology Department in the latest 3-month period of June, July and August (or the latest 3 months available) with the treatments I have provided below?

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st of June 2025, they can be classed as a new patient for the purposes of this question.

- Adalimumab [Humira]
- Adalimumab [All Biosimilars]
- Etanercept [Enbrel]
- Etanercept [All Biosimilars]
- Infliximab [Remicade]
- Infliximab [All Biosimilars]
- Ustekinumab [Stelara]
- Ustekinumab [All Biosimilars]
- Apremilast [Otezla]
- Bimekizumab [Bimzelx]
- Brodalumab [Kyntheum]
- Certolizumab [Cimzia]
- Deucravacitinib [Sotyktu]
- Dimethyl Fumarate [Skilarence]
- Guselkumab [Tremfya]
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Secukinumab [Cosentyx]
- Spesolimab [Spevigo]
- Tildrakizumab [illumetri]

Our response:

Unfortunately, we are unable to identify the number of "new patients" or those specifically treated for Psoriasis, as this detailed information is not recorded within our Medicines Management electronic system.

We therefore confirm that the Health Board does not centrally record this specific information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.